Notes: Fexapotide (trifluoroacetate) is a peptide.{68768} It induces apoptosis in LNCaP prostate cancer cells when used at a concentration of 2.5 mg/ml. Intraprostatic administration of fexapotide triflutate (0.6 mg/animal per week) reduces the numbers of prostate glandular epithelial cells without affecting other cell types and decreases prostate volume in rats.